These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 8841028)
1. Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol. Muggia FM; Synold TW; Newman EM; Jeffers S; Leichman LP; Doroshow JH; Johnson K; Groshen S J Natl Cancer Inst; 1996 Oct; 88(20):1495-6. PubMed ID: 8841028 [No Abstract] [Full Text] [Related]
2. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624 [TBL] [Abstract][Full Text] [Related]
3. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. Synold TW; Newman EM; Carroll M; Muggia FM; Groshen S; Johnson K; Doroshow JH Clin Cancer Res; 1998 Oct; 4(10):2349-55. PubMed ID: 9796964 [TBL] [Abstract][Full Text] [Related]
4. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue. Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277 [TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement. Wedge SR; Laohavinij S; Taylor GA; Boddy A; Calvert AH; Newell DR Clin Cancer Res; 1995 Dec; 1(12):1479-86. PubMed ID: 9815947 [TBL] [Abstract][Full Text] [Related]
7. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Alati T; Worzalla JF; Shih C; Bewley JR; Lewis S; Moran RG; Grindey GB Cancer Res; 1996 May; 56(10):2331-5. PubMed ID: 8625328 [TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis. Budman DR; Johnson R; Barile B; Bowsher RR; Vinciguerra V; Allen SL; Kolitz J; Ernest CS; Kreis W; Zervos P; Walling J Cancer Chemother Pharmacol; 2001 Jun; 47(6):525-31. PubMed ID: 11459206 [TBL] [Abstract][Full Text] [Related]
10. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Chattopadhyay S; Tamari R; Min SH; Zhao R; Tsai E; Goldman ID Oncologist; 2007 Jul; 12(7):808-15. PubMed ID: 17673612 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744 [TBL] [Abstract][Full Text] [Related]
12. [Pancytopenia in rheumatoid arthritis treated with methotrexate]. Laroche F; Perrot S; Menkès CJ Presse Med; 1996 Sep; 25(25):1144-6. PubMed ID: 8949606 [TBL] [Abstract][Full Text] [Related]
13. Design, conduct, and interpretation of organ impairment studies in oncology patients. Takimoto CH; Mita AC J Clin Oncol; 2006 Jul; 24(21):3509-10; author reply 3510-1. PubMed ID: 16849773 [No Abstract] [Full Text] [Related]
14. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet. Habeck LL; Chay SH; Pohland RC; Worzalla JF; Shih C; Mendelsohn LG Cancer Chemother Pharmacol; 1998; 41(3):201-9. PubMed ID: 9443636 [TBL] [Abstract][Full Text] [Related]
15. Accumulation of plasma reduced folates after folic acid administration. Priest DG; Schmitz JC; Bunni MA Semin Oncol; 1999 Apr; 26(2 Suppl 6):38-41. PubMed ID: 10598553 [TBL] [Abstract][Full Text] [Related]
16. Folate during antifolate chemotherapy: what we know... and do not know. Robien K Nutr Clin Pract; 2005 Aug; 20(4):411-22. PubMed ID: 16207681 [TBL] [Abstract][Full Text] [Related]
17. [Accidental shortening time of high dose methotrexate infusion: case report and literature review]. Charfi R; Salouage I; Trabelsi S; Zarrouk M; Gaïes E; Jebabli N; Meddeb B; Lakhal M; Klouz A Ann Biol Clin (Paris); 2013; 71(2):219-22. PubMed ID: 23587592 [TBL] [Abstract][Full Text] [Related]
18. Cytotoxic anticancer agents and renal impairment study: the challenge remains. Rahman A; White RM J Clin Oncol; 2006 Feb; 24(4):533-6. PubMed ID: 16391294 [No Abstract] [Full Text] [Related]
19. A Woman With Severe Rash. Schall C; Cumpston KL; Lenczowski J; Wills BK Ann Emerg Med; 2018 Aug; 72(2):128-165. PubMed ID: 30031506 [No Abstract] [Full Text] [Related]
20. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]